144 related articles for article (PubMed ID: 31119683)
1. Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer.
Tsuboi K; Uematsu C; Yamaguchi Y; Niwa T; Hayashi SI
Breast Cancer; 2019 Nov; 26(6):748-757. PubMed ID: 31119683
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
Chen Z; Wang Y; Warden C; Chen S
J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
[TBL] [Abstract][Full Text] [Related]
5. Estrogen response element-GFP (ERE-GFP) introduced MCF-7 cells demonstrated the coexistence of multiple estrogen-deprivation resistant mechanisms.
Fujiki N; Konno H; Kaneko Y; Gohno T; Hanamura T; Imami K; Ishihama Y; Nakanishi K; Niwa T; Seino Y; Yamaguchi Y; Hayashi S
J Steroid Biochem Mol Biol; 2014 Jan; 139():61-72. PubMed ID: 24128438
[TBL] [Abstract][Full Text] [Related]
6. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
[TBL] [Abstract][Full Text] [Related]
7. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Gilani RA; Kazi AA; Shah P; Schech AJ; Chumsri S; Sabnis G; Jaiswal AK; Brodie AH
Breast Cancer Res Treat; 2012 Oct; 135(3):681-92. PubMed ID: 22878889
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
[TBL] [Abstract][Full Text] [Related]
10. AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Wong C; Wang X; Smith D; Reddy K; Chen S
Breast Cancer Res Treat; 2012 Jul; 134(2):671-81. PubMed ID: 22706627
[TBL] [Abstract][Full Text] [Related]
11. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Masri S; Phung S; Wang X; Wu X; Yuan YC; Wagman L; Chen S
Cancer Res; 2008 Jun; 68(12):4910-8. PubMed ID: 18559539
[TBL] [Abstract][Full Text] [Related]
13. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Hole S; Pedersen AM; Lykkesfeldt AE; Yde CW
Breast Cancer Res Treat; 2015 Feb; 149(3):715-26. PubMed ID: 25667100
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
16. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
17. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
18. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
19. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
20. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]